Gilead Sciences Inc. (NASDAQ:GILD) was downgraded by equities researchers at Leerink Swann from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Tuesday. They presently have a $94.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $112.00. Leerink Swann’s target price suggests a potential upside of 19.03% from the stock’s current price.
Several other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday. Bank of America Corp. reissued a “neutral” rating and set a $100.00 target price on shares of Gilead Sciences in a research note on Sunday. Gabelli reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 23rd. Piper Jaffray Cos. set a $108.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, September 22nd. Finally, Jefferies Group restated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a research report on Thursday, September 22nd. Eleven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $104.34.
Gilead Sciences (NASDAQ:GILD) opened at 78.97 on Tuesday. The company’s 50 day moving average is $79.44 and its 200-day moving average is $85.67. The stock has a market cap of $104.21 billion, a PE ratio of 6.93 and a beta of 1.06. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s quarterly revenue was down 5.7% on a year-over-year basis. During the same quarter last year, the company earned $3.15 EPS. On average, equities analysts anticipate that Gilead Sciences will post $11.76 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.38%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
In other news, Chairman John C. Martin sold 100,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $84.73, for a total value of $8,473,000.00. Following the sale, the chairman now owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Following the completion of the sale, the executive vice president now owns 63,122 shares in the company, valued at approximately $5,246,700.64. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the stock. Cue Financial Group Inc. boosted its position in Gilead Sciences by 32.2% in the first quarter. Cue Financial Group Inc. now owns 9,929 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 2,420 shares in the last quarter. Capital Investment Advisors LLC boosted its position in Gilead Sciences by 2.3% in the first quarter. Capital Investment Advisors LLC now owns 11,933 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 266 shares in the last quarter. Alpha Windward LLC boosted its position in Gilead Sciences by 166.2% in the first quarter. Alpha Windward LLC now owns 7,310 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 4,564 shares in the last quarter. Burke & Herbert Bank & Trust Co. boosted its position in Gilead Sciences by 36.2% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 4,835 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 1,285 shares in the last quarter. Finally, Koshinski Asset Management Inc. boosted its position in Gilead Sciences by 24.1% in the first quarter. Koshinski Asset Management Inc. now owns 7,168 shares of the biopharmaceutical company’s stock worth $683,000 after buying an additional 1,392 shares in the last quarter. Institutional investors own 77.94% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.